SABS
SABS
NASDAQ · Biotechnology

Sab Biotherapeutics Inc

$3.85
+0.02 (+0.52%)
As of Mar 29, 10:35 PM ET ·
Financial Highlights (FY 2025)
Revenue
92.27M
Net Income
5.58M
Gross Margin
29.3%
Profit Margin
6.1%
Rev Growth
-8.1%
D/E Ratio
0.85
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.3% 29.3% 29.3%
Operating Margin 7.9% 7.4% 8.2%
Profit Margin 6.1% 5.3% 6.3%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 92.27M 83.15M 89.97M
Gross Profit 27.05M 24.38M 26.38M
Operating Income 7.29M 6.18M 7.35M
Net Income 5.58M 4.38M 5.69M
Gross Margin 29.3% 29.3% 29.3%
Operating Margin 7.9% 7.4% 8.2%
Profit Margin 6.1% 5.3% 6.3%
Rev Growth -8.1% +18.1% +3.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 83.44M 77.12M 70.96M
Total Equity 98.15M 101.26M 94.04M
D/E Ratio 0.85 0.76 0.75
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 11.07M 10.58M 10.22M
Free Cash Flow 5.66M 4.59M 4.29M